--- title: "Sight Sciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.7 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285431555.md" datetime: "2026-05-06T20:21:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285431555.md) - [en](https://longbridge.com/en/news/285431555.md) - [zh-HK](https://longbridge.com/zh-HK/news/285431555.md) --- # Sight Sciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.7 M Revenue: As of FY2026 Q1, the actual value is USD 19.7 M, beating the estimate of USD 18.55 M. EPS: As of FY2026 Q1, the actual value is USD -0.24, missing the estimate of USD -0.1745. EBIT: As of FY2026 Q1, the actual value is USD -11.89 M. ### First Quarter 2026 Financial Results #### Revenue - **Total Revenue**: Sight Sciences, Inc. generated total revenue of $19.7 million in the first quarter of 2026, marking a 13% increase compared to the same period in the prior year. - **Surgical Glaucoma Revenue**: Surgical Glaucoma revenue was $18.3 million in the first quarter of 2026, an increase of 7% from $17.1 million in the same period in the prior year. - **Dry Eye Revenue**: Dry Eye revenue reached $1.4 million in the first quarter of 2026, representing a 244% increase from $0.4 million in the same period in the prior year and an 87% increase from the fourth quarter of 2025. #### Gross Margin - **Total Gross Profit**: The total gross profit for the first quarter of 2026 was $17.0 million, up from $15.1 million in the prior year period. - **Total Gross Margin**: The total gross margin was 86% in the first quarter of 2026, flat compared to the same period in the prior year. - **Surgical Glaucoma Gross Margin**: Surgical Glaucoma gross margin was 87.2% in the first quarter of 2026, compared to 86.6% in the prior year period. - **Dry Eye Gross Margin**: Dry Eye gross margin was 72.1% in the first quarter of 2026, up from 70.6% in the prior year period. #### Operating Expenses - **Total Operating Expenses**: Total operating expenses were $29.4 million in the first quarter of 2026, a 2% increase from $29.0 million in the same period in the prior year. - **Research and Development Expenses**: Research and development expenses decreased by 43% to $2.5 million in the first quarter of 2026, compared to $4.4 million in the prior year period. - **Selling, General, and Administrative Expenses**: Selling, general, and administrative expenses increased by 9% to $26.8 million in the first quarter of 2026, compared to $24.5 million in the prior year period. - **Adjusted Operating Expenses**: Adjusted operating expenses were $21.2 million in the first quarter of 2026, a 14% decrease compared to $24.7 million in the prior year period. #### Net Loss - **Net Loss**: Sight Sciences, Inc. reported a net loss of - $13.0 million, or a loss of - $0.24 per share, in the first quarter of 2026, an improvement from a net loss of - $14.2 million, or a loss of - $0.28 per share, in the same period in the prior year. #### Cash and Debt - **Cash and Cash Equivalents**: Cash and cash equivalents totaled $85.0 million as of March 31, 2026, down from $92.0 million as of December 31, 2025. - **Cash Usage**: Cash usage in the first quarter of 2026 was $7.0 million, a 40% improvement compared to $11.6 million in the first quarter of 2025. - **Long-term Debt**: Total long-term debt was $40.0 million (before debt discount and amortized debt issuance costs) as of March 31, 2026, consistent with $40.0 million as of December 31, 2025. #### Other Key Metrics - **Patent Infringement Award**: The company was awarded past monetary damages of $55.4 million and an ongoing royalty of 10% of Hydrus® Microstent revenue through patent expiration from Alcon Inc. - **Surgical Glaucoma Active Customers**: The number of active customers for Surgical Glaucoma products was 1,175 in Q1 2026, up from 1,108 in Q1 2025. - **Dry Eye Lid Treatment Units Sold**: Dry Eye lid treatment units sold were 1,534 in Q1 2026, compared to 1,029 in Q1 2025. - **Dry Eye Active Customers**: The number of active customers for Dry Eye products was 96 in Q1 2026, up from 75 in Q1 2025. ### 2026 Financial Guidance Sight Sciences, Inc. raised its full-year 2026 revenue guidance to a range of $83.0 million to $89.0 million, representing 7% to 15% growth over full-year 2025, an increase from its prior guidance of $82.0 million to $88.0 million. This updated guidance includes Interventional Glaucoma segment revenue of $77.0 million to $81.0 million and Interventional Dry Eye segment revenue of $6.0 million to $8.0 million. The company reaffirmed its full-year 2026 adjusted operating expenses guidance range of $93.0 million to $96.0 million, reflecting targeted investments in both business segments. ### Related Stocks - [SGHT.US](https://longbridge.com/en/quote/SGHT.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md) - [GE Vernova Declares Third Quarter 2026 Dividend | GEV Stock News](https://longbridge.com/en/news/286966387.md)